Maze Therapeutics recruiting Phase 2 trial of MZE782 tablets in adult PKU patients
Maze Therapeutics has begun enrollment in a placebo-controlled Phase 2 study testing MZE782 tablets in adults with phenylketonuria.
Maze Therapeutics has one active registry update this week involving its PKU program.
- Maze Therapeutics is recruiting for a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the safety, tolerability, and efficacy of MZE782 in adults with Phenylketonuria (PKU), designated NCT07694440 with the acronym CIPheR.1 The trial is enrolling participants aged 18 to 75 years with a clinical diagnosis of PKU1, testing MZE782 tablets in low dose and high dose formulations against a placebo tablet1, with an estimated enrollment of 38 participants1 and a primary completion date estimated for December 20271.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.